Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 22nd Preview)
-
FDA blocks Capricor Duchenne therapy again
The FDA rejected Capricor’s Duchenne cell therapy deramiocel for a second time, citing “serious data integrity violations” that compromised the company’s study findings. The regulator’s action adds another setback for the late-stage development of a platform aimed at improving cardiac and skeletal muscle function in Duchenne muscular dystrophy. Capricor now faces the task of addressing the specific compliance and data validation issues identified by the agency before resubmission. The second complete rejection highlights how quality-system and evidence-pack issues can be as decisive as clinical results in getting therapies across the finish line. For the wider cell therapy sector, the decision reinforces the scrutiny applied to manufacturing consistency, endpoint reporting, and the defensibility of trial data, particularly when investigational products rely on complex biological processes.
-
New phase 2 signal for Tislelizumab plus Lenvatinib in rare kidney cancer
A randomized phase 2 study reports efficacy for tislelizumab combined with lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma, with strong objective response rates and continued follow-up needed for durability. The trial adds to the growing use of dual-checkpoint and VEGF-pathway combinations in genetically defined renal cancers. While the dataset size remains typical for a phase 2 program in a rare molecular subgroup, the results matter for clinicians because fh-deficient RCC often has limited standard options. The combination also mirrors a strategy used across other tumor types—pairing PD-1 blockade with angiogenesis inhibition—to boost response rates. Developers will likely focus next on durability, safety management, and biomarker work that can identify which patients benefit most from the regimen.
-
Phase 3 update: Tislelizumab boosts overall survival in advanced esophageal cancer
In advanced esophageal squamous cell carcinoma, adding tislelizumab to first-line chemotherapy extends overall survival over three years of follow-up in a randomized phase 3 trial. The long-horizon data strengthen the durability profile of the regimen compared with chemotherapy alone. The result supports the increasing shift toward PD-1-based combinations as a backbone in upper GI oncology, particularly for patient populations with limited durable outcomes from chemotherapy. Longer follow-up also helps clarify whether treatment benefit persists beyond early response. Clinicians will now weigh the updated survival evidence against toxicity and sequencing considerations, while companies will likely use the dataset to inform future trial design in earlier lines and biomarker-enriched populations.
-
Dual immunotherapy before surgery improves recurrent glioblastoma outcomes
A randomized surgical window-of-opportunity trial reports that giving dual immune checkpoint blockade before resection increases immune infiltration in recurrent glioblastoma and correlates with extended patient survival. The design uses presurgical therapy to rapidly observe tumor immune remodeling during a defined time window. For glioblastoma, where treatment resistance and immune exclusion remain major obstacles, the study offers clinical evidence that timing and tumor accessibility can meaningfully change the immune microenvironment. The immune infiltration signal provides a measurable pharmacodynamic endpoint for future studies. The data also set up a clearer rationale for neoadjuvant immunotherapy strategies in brain tumors, where post-surgical access and immunosuppressive biology complicate later immune activation.
-
New clinical option: Canakinumab improves outcomes in unresectable stage III lung cancer
Interleukin-1 beta inhibition with canakinumab, when added to concurrent chemoradiotherapy and durvalumab, shows favorable progression-free survival in the phase I/II CHORUS trial for unresectable stage III non-small cell lung cancer. The reported 24-month PFS rate of 67% comes from an early-stage safety-and-activity design. The combination targets an inflammatory pathway implicated in tumor progression and treatment response, aligning IL-1 biology with current checkpoint-containing thoracic regimens. For patients with stage III disease, where cure rates remain modest and systemic control is a persistent challenge, the signal expands the menu of investigational add-ons. Future work will need to define comparative effectiveness versus standard of care, characterize safety trade-offs, and identify any responders using inflammatory or tumor microenvironment biomarkers.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.